CANCER BREAKTHROUGH New breast cancer wonder drug slashes risk of tumours returning or spreading by 37 per cent

New breast cancer wonder drug slashes risk of tumours returning or spreading by 37 per cent

The findings are from a study of those suffering from triple negative breast cancer, which is much more likely to affect the under-40s.

The drug, already used to treat other cancers, works by stimulating the immune system so that it can recognise and attack a tumour.

Lead researcher Professor Peter Schmid, of Queen Mary University of London, said: “We now have long-term results that show the cure rate for these cancers is significantly increased.”

Pembrolizumab has already been approved for treatment of breast cancer in the US. Experts hope the latest results will mean the NHS does likewise.

Every year in the UK, 8,000 women are diagnosed with triple negative breast cancer.

Dr Kotryna Temcinaite, from Breast Cancer Now, said: “This promising new treatment could potentially prevent more lives being lost to this devastating disease.

“We desperately need new and effective treatments.”

We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies. Learn more